Foghorn Therapeutics Inc.
FHTX
$4.88
-$0.18-3.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.69% | 11.64% | 4.77% | 3.43% | -1.99% |
| Total Depreciation and Amortization | -5.87% | 0.12% | 2.90% | 8.67% | 3.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 120.99% | -19.24% | 14.50% | 41.89% | -10.54% |
| Change in Net Operating Assets | -18.22% | 10.16% | 16.85% | -14.35% | -55.12% |
| Cash from Operations | -18.09% | 10.19% | 12.38% | 2.25% | -16.73% |
| Capital Expenditure | -- | 100.00% | 21.43% | 94.15% | -55.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -62.80% | 5.07% | 15.04% | 29.24% | 137.32% |
| Cash from Investing | -62.80% | 5.14% | 15.08% | 31.90% | 136.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,085.71% | -80.71% | 82.73% | 3,375.00% | -99.72% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 1,085.71% | -80.71% | 82.73% | 3,375.00% | -99.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -150.46% | 28.07% | 134.89% | 350.54% | 97.26% |